SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (26601)11/18/1998 9:18:00 AM
From: Mudcat  Read Replies (1) | Respond to of 32384
 
< The lone negative vote was based on the perception that the drug "wasn't worth it">

I sure hope this perception doesn't spread! Although over the past six months I must say I and many others on the thread have been having this same perception.



To: Henry Niman who wrote (26601)11/18/1998 9:40:00 AM
From: jayhawk969  Read Replies (1) | Respond to of 32384
 
Henry,

LGND is currently conducting trials for treating KS with an oral version of Panretin.

Will oral be systemic and thus do more than the topical gel?

TIA

J.D.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News